top of page
DNA Strand

About Us

We have an investor-operator mindset and adopt a hands-on portfolio management approach, providing talent sourcing, financial and operational value-add within a global support ecosystem.

About: About

Meet Our Team

Get to know us

About: Text
TY pic cropped.PNG

Dr Poon Thong Yuen

Founder and General Partner

About: CV

Thong Yuen is a seasoned investment professional who has about 15 years of global experience in VC investments. He joined EDBI/ Bio*One Capital in early 2004, and has been involved in various therapeutics, medtech and healthcare services investments. Main geographical areas covered include USA (based in Boston from 2008-2011), China, Australia and Japan. Select biomedical sciences investments that Thong Yuen was involved in include Artisan Pharma (acquired by Asahi Kasei Pharma), Dx Assay (JV with Qiagen), Inviragen (acquired by Takeda Pharmaceutical), Forma Therapeutics (NASDAQ-listed), Rapid Micro Biosystems (NASDAQ-listed) and Ivantis (acquired by Alcon). Notable digital media investments include Scan Scout (acquired by Tremor Media) and Crisp Media. He also led the team that set up a Joint-Investment Committee for Digital Health with Royal Philips. Before leaving EDBI, he was leading the healthcare team as VP Investments and a voting member of the Investment Committee.

Observing modest investment activity within the local healthcare ecosystem, Thong Yuen started to work with Singapore-based accelerators/ investors like Zicom (as Chief Investment Officer) and Venturecraft (as Investment Advisor), in a bid to facilitate investments into local companies. Thong Yuen also contributed on the Board of Directors of select local companies, including Hyphens Pharma (SGX-listed).

His previous research experience includes computer-aided drug design, medicinal chemistry, radio-ligand binding assays and animal studies. Thong Yuen also has a good background in community pharmacy and pharmaceutical manufacturing processes. He earned his doctorate in Medicinal Chemistry and honours degree in Pharmacy from the National University of Singapore.


Ong Jeong Shing

Founder and General Partner

About: CV

Jeong Shing (JS) has over 15 years of global healthcare experience across corporate pharma, technology management and venture capital, including incubating and building early stage life science companies. He was Partner at EDBI, the strategic venture arm of the Economic Development Board of Singapore, leading healthcare investments in biotech, medtech, digital health and life science tools, as well as Fund of Fund investments. His investment track record and network span key geographies including USA, China, Singapore and Southeast Asia, which is complemented by his operational experience in helping portfolio companies pursue international expansion.

Prior to EDBI, JS oversaw investments at Venturecraft, a Singapore based boutique venture capital firm and multi-family office focusing on tech and healthcare. He successfully set up a digital health incubator supported by the Singapore government and nurtured several successful start up companies such as US2.AI, Hearti Labs and Aktivo. He also established a life science accelerator in Hangzhou China, to help portfolio companies accelerate product and clinical development and gain rapid access to the Chinese market. Before starting his venture career, JS led process development and scale up at Glaxosmithkline, working across UK, US and Singapore and on multiple assets in oncology and respiratory diseases. 

His select healthcare investments include Kaleido Biosciences (NASDAQ: KLDO), Mirxes, Doctor Anywhere, Aetion, Neuroglee, Engine Biosciences and Immunoscape.

JS earned First Class Honours Degrees in Bioengineering and Chemical Engineering from the National University of Singapore, and holds an MBA with distinction from the University of Cambridge, specializing in Private Equity.

bottom of page